Treat raises €3M to fix private healthcare’s broken economics—by redesigning the incentive
Finnish healthtech startup Treat has raised €3 million in a pre-seed round led by early-stage backer byFounders and Illusian, the investment vehicle of Supercell co-founder Ilkka Paananen. The company’s approach targets a core flaw in private healthcare: a system where providers profit from the number of visits rather than the quality of care, leaving patients trapped in cycles of unnecessary appointments.
The issue hit close to home for Treat co-founder Sami Marttinen, who previously led fintech startup Swappie. When his wife needed medical attention three years ago, she required nine separate visits before receiving a diagnosis—despite all the necessary information being available. The problem wasn’t a lack of data, but a lack of alignment between how doctors are compensated and how efficiently care is delivered.
Treat aims to break this cycle by streamlining the consultation process. The company uses AI to structure patient symptoms into a clear medical brief before a doctor even joins the call, ensuring physicians have the full context upfront. Most cases are resolved in a single digital consultation, while more complex ones are routed directly to specialists—without the need for referrals, lab-test upcharges, or prolonged engagement. The company’s revenue model is tied to resolving patient issues, not extending care.
This strategy reflects a broader trend in healthtech, where startups are targeting inefficiencies in primary care. Earlier this month, *StartupReader* covered Confido Health’s $12.5 million Series A extension, which focused on automating administrative tasks. Treat, however, takes a different approach by addressing the financial incentives that sustain inefficiency.
Yet scaling this model presents challenges. Private healthcare markets are deeply entrenched, with established players relying on referral networks and lab-test revenue. Treat’s insistence on avoiding these traditional revenue streams is a bold stance, but it remains unclear whether the company can compete without adopting similar practices. If adoption grows, it could pressure incumbent clinics to reform—or risk losing patients to a more efficient alternative.
Illusian’s involvement, alongside byFounders’ backing, suggests confidence in Treat’s ability to navigate regulatory and clinical hurdles. However, the company will need to demonstrate real-world traction beyond its initial employer-based access. For now, the focus is on efficiency: replacing multiple visits with a single, well-informed consultation.
What to watch next: Whether Treat can expand beyond employer-based access to direct consumer adoption, a riskier path in private healthcare. How incumbent clinics respond—will they adopt more efficient models, or double down on traditional revenue structures? Whether the AI intake system holds up in complex cases where symptom description alone isn’t sufficient.
The €3 million round is a small but deliberate bet on fixing a broken system. Whether it’s enough to change the industry’s incentives remains uncertain.
Sources: tech.eu
“The funding signals a push to address systemic inefficiencies in private healthcare, where financial structures often prioritize prolonged engagement over patient outcomes—but whether Treat’s model can reshape the industry remains an open question.”
One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.
Read the original reporting
The outlets below did the original reporting.
Related briefs
- MegaRobo’s $200M Haul Leads Asia’s $335M Funding Week as Semiconductors and AI Infrastruct
- Archer Raises $10M to Fix AI’s Broken Hiring Arms Race—With a Bipartisan Platform
- AI startup Dreamteam bets $53M on CRM automation—can it outmaneuver Salesforce and SAP?
- India’s AI Funding Boom Hides a Critical Weakness: Can It Build a Foundational Player?
- BrightAI raises $97M to expand AI-driven industrial monitoring with GE Vernova partnership
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.